Roche AG

Grenzacherstrasse 124, 4070 Basel
Roche AG  
Location: Basel
Discipline: Pharmacology
Pharmacology - Health - Sep 23
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medicine's FoundationOne Liquid biopsy assay to identify patients who may be eligible for Alecensa (alectinib) First results from the positive Phase III I
Health - Pharmacology - Sep 20

Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infection can be fatal in patients receiving blood transfusions from infected donors The availability of

Pharmacology - Health - Sep 16

Cobas pro integrated solutions improves productivity in the lab and enhances reliability and turnaround times in delivering results to patients By simplifying operations in the lab, Roche is in-turn helping physicians provide evidence-based diagnostic and treatment decisions more cost-effectively

Pharmacology - Health - Sep 13

New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, including the US Food and Drug Administration and European Medicines Agency Results will be presented

Pharmacology - Health - Sep 12

Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)Bullet Roche today announced positive data from the Phase III IMpower110 study evaluating Tecentriq (atezolizumab) as a first-line (initial) monotherapy com

Pharmacology - Health - Sep 18

There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with standard of care, helped more people achieve a complete renal response than standard of care alone Fu

Pharmacology - Health - Sep 13

Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study s

Pharmacology - Health - Sep 12

Roche's satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum.

Pharmacology - Health - Sep 10

Blood neurofilament light chain (NfL) levels were significantly lowered following OCREVUS treatment in analyses of Phase III studies in RMS and PPMS New data show NfL may be a biomarker for predicting future disability outcomes Separate analyses presented from one of the first studies to demonstr





website preview

Link

Medicine and Life Sciences